Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch-Schönlein purpura nephritis
{{output}}
Aim: This study aimed to evaluate the impact of CYP3A5 gene polymorphism on the pharmacokinetics, therapeutic efficacy, and safety of tacrolimus in pediatric patients with Henoch-Schönlein purpura nephritis (HSPN). ... ...
